Metabolic Ledger

Is Your Telehealth Provider Still Compounding GLP-1s?

Every major US telehealth provider that has, or has recently had, a GLP-1 weight-loss offering. Status is checked weekly. Each row links to the source we used to confirm it.

Last full scan: Aug 31, 2026 (3 days ago) — refreshes Mondays 06:00 UTC. Page is regenerated within the hour of an operator-approved change.

Cite, embed, or download this tracker →

ProviderStatusPricingNotesLast verifiedSourceCite
Hims & Hers#Brand-name only$149/mo intro (Wegovy oral); $349/mo Wegovy stdSettled with Novo 2026-03-09; offers FDA-approved Wegovy + OzempicMay 27, 2026link
Ro#Mixed (brand + compounded)$145-249/mo compounded; brand at NovoCare/LillyDirect cashBrand + compounded under §503A(b)(1)(D) framingMay 27, 2026link
Mochi Health#Still compounding$199-299/mo compounded semaglutideActive Lilly suit; FDA warning letter pendingAug 31, 2026link
Henry Meds#Still compounding$249-349/mo compoundedActive Lilly suit on tirzepatideMay 27, 2026link
Fella Health#Still compounding$199-299/mo compoundedActive Novo suit; FDA warning-letter recipientAug 31, 2026link
Willow Health#Still compounding$179-249/mo compoundedActive litigation; smaller-volume providerMay 27, 2026link
Eden Weight Loss#Still compounding$269/mo+ compoundedPremium-positioned compounded providerMay 27, 2026link
Plushcare#Brand-name onlyInsurance + savings card; cash via NovoCare/LillyDirectInsurance-friendly; brand-name onlyAug 31, 2026link
Calibrate#Brand-name onlyProgram fee + brand prescription separatelyInsurance-first program; brand-name onlyAug 31, 2026link
WeightWatchers Clinic#Brand-name onlyProgram fee + brand at member pricingAcquired Sequence; brand-onlyMay 27, 2026link
Form Health#Brand-name onlyInsurance + visit fees; brand prescriptionsObesity-medicine clinic model; insurance-billing focusAug 31, 2026link

Get told the moment your compounder's status changes.

We track every FDA warning letter, state enforcement action, and 503A/503B status change across the major compounded-GLP-1 providers — and email you when something moves that affects your script. Free, no spam, one-click unsubscribe.

Answering is optional and is your consent for us to store it, only so we send content that fits your stage. We never share or sell it, and you can ask us to delete it anytime.

We don’t share or sell your email. Unsubscribe anytime in one click. See our privacy policy.

How we determine status

Once a week, we re-fetch each provider’s GLP-1 marketing page, capture the relevant text, and classify it against five statuses (still compounding / brand-only / mixed / wound-down / unconfirmed). A classifier proposes any change; an editor reviews the proposed change against the captured source quote before it goes live. We never auto-publish a status flip. The complete process is on the methodology page.

Why this changes so fast

The regulatory backdrop — FDA shortage resolutions, the OFA litigation, the Eli Lilly and Novo Nordisk patent and trademark suits, and FDA warning letters — has been moving on weekly timescales since late 2024. A row can flip between status states based on a single court ruling, a settlement, or a manufacturer enforcement action. See our compounding-cliff timeline for the long-form regulatory chronology and the FDA warning-letters tracker for the active enforcement docket.

Recent changes (last 30 days)

  • May 29, 2026: mochi — current_status changed from still_compounding to still_compounding. Source.
  • May 29, 2026: fella — current_status changed from still_compounding to still_compounding. Source.
  • May 29, 2026: plushcare — current_status changed from brand_only to brand_only. Source.
  • May 29, 2026: calibrate — current_status changed from brand_only to brand_only. Source.
  • May 29, 2026: form-health — current_status changed from brand_only to brand_only. Source.

How to use this page

  • Watching what it costs? Our GLP-1 Price Index tracks the median monthly cash price across providers over time — compounded vs brand — so you can see where the market is heading, not just who still compounds.
  • Considering a provider? Their status here is one input. Read our scoring methodology for the other six dimensions we use to compare providers.
  • Currently on compounded GLP-1? The switch-to-brand guide and Hims wind-down explainer cover what to expect when a provider stops compounding mid-treatment.
  • Spotted an error? Email [email protected] with the provider name + a source link. We acknowledge within five business days and update within fifteen.